Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) Stock Rating Cut to Strong Sell at Wall Street Zen

Posted by Donna Armstrong on Nov 8th, 2026

Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Free Report) from a sell rating to a strong sell rating in a research note released on Saturday,Wall Street Zen reports.

Other equities analysts have also recently issued reports about the stock. HC Wainwright initiated coverage on shares of Lakewood-Amedex Biotherapeutics in a research note on Wednesday, October 28th. They set a “buy” rating for the company. Weiss Ratings upgraded shares of Lakewood-Amedex Biotherapeutics from a “sell (e-)” rating to a “sell (e)” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold”.

View Our Latest Research Report on LABT

Lakewood-Amedex Biotherapeutics Stock Performance

Shares of LABT opened at $0.39 on Friday. The stock has a fifty day moving average of $1.19. The company has a market capitalization of $915,531.00 and a P/E ratio of -0.08. Lakewood-Amedex Biotherapeutics has a 52-week low of $0.17 and a 52-week high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($2.75) earnings per share for the quarter. On average, sell-side analysts anticipate that Lakewood-Amedex Biotherapeutics will post 4.96 EPS for the current year.

About Lakewood-Amedex Biotherapeutics

(Get Free Report)

Lakewood-Amedex Biotherapeutics, Inc is a biotechnology company focused on the research and development of anti-infective therapies. Its work centers on developing treatments designed to address infections caused by bacteria and other pathogens.

The company’s activities are primarily directed toward advancing a pipeline of investigational therapeutic candidates rather than selling a broad portfolio of marketed products. Its development programs have focused on potential applications in human health, including treatments for localized and systemic infections.

Publicly available information about Lakewood-Amedex Biotherapeutics’ current product pipeline, commercial operations, geographic reach, and leadership is limited.